Recombinant expressing angiopep-2 fused anti-VEGF single chain Fab (scFab) could cross blood–brain barrier and target glioma
Abstract In 2009, the FDA approved bevacizumab for the treatment of adult patients diagnosed with recurrent glioblastoma. However, the poor permeability of the macromolecules across the blood–brain barrier, determined by multifactorial anatomical and physiological milieu, restricts the clinical ther...
Main Authors: | Xuemei Ji, Hongyan Wang, Yue Chen, Junfei Zhou, Yu Liu |
---|---|
Format: | Article |
Language: | English |
Published: |
SpringerOpen
2019-10-01
|
Series: | AMB Express |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s13568-019-0869-3 |
Similar Items
-
Self-assembled angiopep-2 modified lipid-poly (hypoxic radiosensitized polyprodrug) nanoparticles delivery TMZ for glioma synergistic TMZ and RT therapy
by: Zhenkun Zong, et al.
Published: (2019-01-01) -
Angiopep-2-conjugated poly(ethylene glycol)-co-poly(ε-caprolactone) polymersomes for dual-targeting drug delivery to glioma in rats
by: Lu F, et al.
Published: (2017-03-01) -
An Angiopep2-PAPTP Construct Overcomes the Blood-Brain Barrier. New Perspectives against Brain Tumors
by: Sofia Parrasia, et al.
Published: (2021-02-01) -
Single chain Fab (scFab) fragment
by: Brenneis Mariam, et al.
Published: (2007-03-01) -
Production of single chain Fab (scFab) fragments in <it>Bacillus megaterium</it>
by: Dübel Stefan, et al.
Published: (2007-11-01)